The trial aims to compare the effectiveness of three methods of conservative treatment of degenerative lumbar spine stenosis (DLSS): GOLDIC autologous serum epidural injections, steroid epidural injections and manual therapy.
BACKGROUND: Degenerative Lumbar Spinal Stenosis (DLSS) is a serious health problem for patients over 65 years of age. It is assumed that in the United States alone, it affects about 200 thousand patients causing significant impairment of their quality of life. Although it is relatively easy to confirm the nature of spinal canal encroaching (disc protrusion, facet hypertrophy, ligamentous folding) by several methods of imaging, the golden standard of DLSS management, especially in the group of older patients, is still the matter of debate. Three main concepts of conservative treatment are considered: 1) pharmacological care - symptom-oriented systemic anty-inflammatory and analgesic agents or local steroid injections, 2) rehabilitations protocols and mechanical devices like traction facilities or corsets to decompress spinal canal or support in case of instability, 3) biological - stimulation of anti-inflammatory action and regeneration capacity by biologically active substances. All methods are offered without strong evidence of its efficacy. AIM: Comparison of the effectiveness of three treatment protocols in DLSS: epidural injections of autologous serum (Gold Induced Cytokines, Goldic), epidural steroid injections, manual therapy in the concept of spinal canal venous drainage. Research hypothesis: The use of Goldic serum in epidural injections improves the condition of patients with DLSS during the observation period longer than steroid injections and the rehabilitation protocol. DESIGN: Randomized prospective trial without blinding. SETTING: Open study for outpatients, single-centre study. POPULATION: the local adult population METHODS: Three groups of patients (A, B, C) with confirmed DLSS in MRI, without limiting sex, age, meeting health conditions according to the inclusion and exclusion criteria. There will be 30 people in each group (90 people in total). Group A - Goldic serum therapy - 4 injections at 3-day intervals containing single doses of serum (4 doses of 3 ml in total), injections performed into the epidural space under ultrasound control by the same operator. Group B - steroid therapy with Dexaven 4 mg / 1 ml - 2 injections at weekly intervals containing single doses of dexamethasone (total dose of 8 mg), injections will be performed into the epidural space under ultrasound control by the same operator. Group C - manual therapy according to the concept of venous drainage - a repeatable treatment scheme for each patient; decompression of the thoracic outlet, diaphragm release, sacroiliac joints (SI) mobilizations, rib-sternum release, rib raising technique - 4 sessions (1 x weekly - approx. 40 min). Control tools: NRS Pain Scale (0-10), Oswestry Disability Index, Zurich Claudication Questionnaire (ZCQ), EQ-5D-5L, Control points: Initial Assessment (IA), 4,12, 24 weeks after last intervention.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
90
epidural injections
epidural injections
Veno-lymphatic drainage
Sutherland Medical Center
Warsaw, Masovian Voivodeship, Poland
Change in EQ-5D-5L index from baseline to 24 weeks
EQ-5D-5L index estimated from EQ-5D-5L desrcriptive system based on Polish directly measured value set. Mininmum: -0.590; Maximum: 1.0; More points means better outcome.
Time frame: Change from baseline to 24 weeks
Change in Oswestry Disability Index from baseline to 24 weeks
Disease-specific questionnaire. Range: 0 (the best score) - 50 (the worst score).
Time frame: Change from baseline to 24 weeks
Change in Zurich Claudication Questionnaire (ZCQ) from baseline to 24 weeks
Disease-specific questionnaire. Range: 12 (the best score) - 55 (the worst score).
Time frame: Change from baseline to 24 weeks
Change in pain intensity according to Numeric Rating Scale
Generic outcome measure. Range: 0 (no pain) - 10 (the worst possible pain).
Time frame: Change from baseline to 4 weeks
Change in pain intensity according to Numeric Rating Scale
Generic outcome measure. Range: 0 (no pain) - 10 (the worst possible pain).
Time frame: Change from baseline to 12 weeks
Change in pain intensity according to Numeric Rating Scale
Generic outcome measure. Range: 0 (no pain) - 10 (the worst possible pain).
Time frame: Change from baseline to 24 weeks
Change in EQ-5D-5L index from baseline to 4 weeks
EQ-5D-5L index estimated from EQ-5D-5L desrcriptive system based on Polish directly measured value set. Mininmum: -0.590; Maximum: 1.0; More points means better outcome.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Change from baseline to 4 weeks
Change in EQ-5D-5L index from baseline to 12 weeks
EQ-5D-5L index estimated from EQ-5D-5L desrcriptive system based on Polish directly measured value set. Mininmum: -0.590; Maximum: 1.0; More points means better outcome.
Time frame: Change from baseline to 12 weeks
Change in Oswestry Disability Index from baseline to 4 weeks
Disease-specific questionnaire. Range: 0 (the best score) - 50 (the worst score).
Time frame: Change from baseline to 4 weeks
Change in Oswestry Disability Index from baseline to 12 weeks
Disease-specific questionnaire. Range: 0 (the best score) - 50 (the worst score).
Time frame: Change from baseline to 12 weeks
Change in Zurich Claudication Questionnaire (ZCQ) from baseline to 4 weeks
Disease-specific questionnaire. Range: 12 (the best score) - 55 (the worst score).
Time frame: Change from baseline to 4 weeks
Change in Zurich Claudication Questionnaire (ZCQ) from baseline to 12 weeks
Disease-specific questionnaire. Range: 12 (the best score) - 55 (the worst score).
Time frame: Change from baseline to 12 weeks